Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
This study has been terminated.
(FDA Hold May 2007)
Sponsor:
Point Therapeutics
Information provided by:
Point Therapeutics
ClinicalTrials.gov Identifier:
NCT00290017
First received: February 9, 2006
Last updated: June 7, 2007
Last verified: June 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | No date given |